121 related articles for article (PubMed ID: 38227933)
21. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
Admiraal R; Nierkens S; Bierings MB; Bredius RGM; van Vliet I; Jiang Y; Lopez-Yurda M; Versluijs AB; Zwaan CM; Lindemans CA; Boelens JJ
Lancet Haematol; 2022 Feb; 9(2):e111-e120. PubMed ID: 35114150
[TBL] [Abstract][Full Text] [Related]
22. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
23. Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.
Wetzel L; Wittig S; Gruhn B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):255-265. PubMed ID: 34120222
[TBL] [Abstract][Full Text] [Related]
24. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
Gao L; Liu J; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Zhong J; Sun A; Du X; Su Y; Li H; Liu H; Peng X; Zhang X
Leuk Res; 2017 Jun; 57():27-36. PubMed ID: 28273549
[TBL] [Abstract][Full Text] [Related]
25. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
26. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.
Gjaerde LK; Ostrowski SR; Minculescu L; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Eur J Haematol; 2021 Mar; 106(3):417-424. PubMed ID: 33314420
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
28. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
29. Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).
Schmelz R; Bornhäuser M; Schetelig J; Kiani A; Platzbecker U; Schwanebeck U; Grählert X; Uharek L; Aust D; Baretton G; Schwerdtfeger R; Hampe J; Greinwald R; Mueller R; Ehninger G; Miehlke S
BMC Gastroenterol; 2014 Nov; 14():197. PubMed ID: 25425214
[TBL] [Abstract][Full Text] [Related]
30. Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
Krstevska S; Genadieva-Stavric S; Pivkova A; Stojanovski Z; Georgievski B; Balkanov T
Med Arh; 2011; 65(5):260-4. PubMed ID: 22073847
[TBL] [Abstract][Full Text] [Related]
31. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.
Bader CS; Pavlova A; Lowsky R; Muffly LS; Shiraz P; Arai S; Johnston LJ; Rezvani AR; Weng WK; Miklos DB; Frank MJ; Tamaresis JS; Agrawal V; Bharadwaj S; Sidana S; Shizuru JA; Fernhoff NB; Putnam A; Killian S; Xie BJ; Negrin RS; Meyer EH
Blood Adv; 2024 Mar; 8(5):1105-1115. PubMed ID: 38091578
[TBL] [Abstract][Full Text] [Related]
32. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
[TBL] [Abstract][Full Text] [Related]
36. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
37. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
Tandra A; Covut F; Cooper B; Creger R; Brister L; McQuigg B; Caimi P; Malek E; Tomlinson B; Lazarus HM; Otegbeye F; Kolk M; de Lima M; Metheny L
Leuk Lymphoma; 2018 Jul; 59(7):1644-1651. PubMed ID: 29199482
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.
Huang R; Chen T; Wang S; Wang J; Su Y; Liu J; Zhang Y; Ma X; Wen Q; Kong P; Zhang C; Gao L; Zhong JF; Gao L; Zhang X
JAMA Oncol; 2024 Feb; 10(2):220-226. PubMed ID: 38153755
[TBL] [Abstract][Full Text] [Related]
39. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy.
Weissinger EM; Metzger J; Schleuning M; Schmid C; Messinger D; Beutel G; Wagner-Drouet EM; Schetelig J; Baurmann H; Rank A; Stolzl F; Schäfer-Eckart K; Westphal K; Bethge W; von Harsdorf S; Bunjes DW; Heidenreich D; Klein S; Holler E; Kreipe HH; Jonigk D; Türüchanow I; Raad J; Papkalla A; von der Leyen H; Hambach L; Hamwi I; Ehrlich S; Krauter J; Stadler M; Ganser A
Leukemia; 2021 Jun; 35(6):1763-1772. PubMed ID: 33082512
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.
Carrillo-Cruz E; García-Lozano JR; Márquez-Malaver FJ; Sánchez-Guijo FM; Montero Cuadrado I; Ferra I Coll C; Valcárcel D; López-Godino O; Cuesta M; Parody R; López-Corral L; Alcoceba M; Caballero-Velázquez T; Rodríguez-Gil A; Bejarano-García JA; Ramos TL; Pérez-Simón JA
Clin Cancer Res; 2019 Aug; 25(15):4616-4623. PubMed ID: 31043390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
